# Inherited Leukodystrophies and Neurometabolic Disease

## Introduction

Leukodystrophies are a group of inherited disorders primarily affecting the white matter of the central nervous system. Neurometabolic diseases encompass a broader category of inborn errors of metabolism with neurological manifestations. While individually rare, collectively these disorders are an important cause of progressive neurological decline in children and adults. Early diagnosis is increasingly critical as disease-modifying therapies, including gene therapy and enzyme replacement, become available for several conditions.

## General Approach to Leukodystrophies

### Clinical Clues

The hallmark presentation is progressive neurological deterioration, which may manifest as motor regression, cognitive decline, or behavioral changes. MRI typically shows confluent, symmetric white matter abnormalities. A family history consistent with autosomal recessive, X-linked, or mitochondrial inheritance strengthens suspicion. Age of onset is particularly helpful in guiding the differential diagnosis. Infantile presentations include Krabbe disease, metachromatic leukodystrophy (MLD), Canavan disease, Alexander disease, and Pelizaeus-Merzbacher disease. Juvenile onset points toward MLD, X-linked adrenoleukodystrophy (X-ALD), and vanishing white matter disease. Adult-onset forms include X-ALD, adult-onset MLD, cerebrotendinous xanthomatosis (CTX), and adult-onset Alexander disease.

### MRI Pattern Recognition

The distribution of white matter abnormalities on MRI is the single most valuable tool for narrowing the differential. Anterior-predominant involvement suggests Alexander disease or late-stage MLD. Posterior-predominant disease is characteristic of X-linked adrenoleukodystrophy and Krabbe disease. Periventricular-predominant changes point toward early MLD and vanishing white matter disease. Subcortical U-fiber involvement is seen in Canavan disease, L-2-hydroxyglutaric aciduria, and megalencephalic leukoencephalopathy. Cerebellar white matter involvement raises suspicion for cerebrotendinous xanthomatosis and type II Alexander disease. Contrast enhancement at the advancing edge of white matter lesions is a hallmark of active inflammatory X-linked adrenoleukodystrophy.

![MRI patterns distinguishing major leukodystrophies by distribution of white matter involvement](images/leukodystrophy-mri-patterns.jpg)

## Major Leukodystrophies

| Leukodystrophy | Gene/Enzyme | Inheritance | MRI Pattern | Treatment |
|---|---|---|---|---|
| Metachromatic (MLD) | ARSA (arylsulfatase A) | AR | Periventricular → diffuse | HSCT (presymptomatic); Gene therapy (Libmeldy) |
| X-linked ALD | ABCD1 (peroxisomal transporter) | X-linked | Posterior-predominant + contrast enhancement | HSCT (early cerebral); Gene therapy (Skysona) |
| Krabbe | GALC (galactocerebrosidase) | AR | Posterior-predominant | HSCT (presymptomatic infants only) |
| Alexander | GFAP (de novo dominant) | AD | Type I: frontal; Type II: brainstem/cerebellar | Supportive only |
| Canavan | ASPA (aspartoacylase) | AR | Diffuse with subcortical U-fibers; elevated NAA on MRS | Supportive only |
| CTX | CYP27A1 | AR | Cerebellar white matter | Chenodeoxycholic acid (treatable!) |

### Metachromatic Leukodystrophy (MLD)

MLD is an autosomal recessive disorder caused by deficiency of arylsulfatase A (ARSA), leading to accumulation of sulfatide in myelin-forming cells including oligodendrocytes and Schwann cells. Three clinical forms exist: the late infantile form (most common, onset 12-30 months), juvenile form (4-12 years), and adult form (onset after puberty). The late infantile form presents with gait deterioration, spasticity, peripheral neuropathy, progressive cognitive decline, and optic atrophy. Diagnosis rests on demonstrating low ARSA enzyme activity in leukocytes, elevated urine sulfatides, and genetic confirmation. Treatment options include hematopoietic stem cell transplantation (HSCT) in presymptomatic or very early symptomatic patients, and gene therapy (atidarsagene autotemcel / Libmeldy), which has been approved in the EU for presymptomatic and early-stage patients.

### X-Linked Adrenoleukodystrophy (X-ALD)

X-ALD is caused by mutations in the ABCD1 gene encoding a peroxisomal membrane transporter, resulting in accumulation of very long chain fatty acids (VLCFAs) in the brain, adrenal glands, and testes. The phenotypic spectrum is wide. Childhood cerebral ALD (onset 4-12 years) is the most devastating form, with rapidly progressive behavioral changes, cognitive decline, vision and hearing loss, and seizures. MRI shows posterior-predominant white matter disease with contrast enhancement, and without treatment the condition is fatal within 2-5 years. Adrenomyeloneuropathy (AMN) affects adult males in their 20s-40s with progressive spastic paraparesis, peripheral neuropathy, and bladder dysfunction; 20-30% may develop cerebral disease. Some patients present with adrenal insufficiency alone, which may precede neurological symptoms by years. Female carriers develop AMN-like symptoms in 50-60% of cases by middle age.

Diagnosis relies on elevated plasma VLCFAs (C26:0 and the C26:0/C22:0 ratio), confirmed by ABCD1 mutation analysis. Treatment with HSCT is effective for early-stage cerebral ALD (Loes score 9 or less). Lorenzo's oil does not prevent cerebral disease but may lower VLCFAs. Gene therapy (elivaldogene autotemcel / Skysona) has been approved for early cerebral ALD. Newborn screening for X-ALD is now included in many states' newborn screening panels, transforming early detection.

### Krabbe Disease (Globoid Cell Leukodystrophy)

Krabbe disease is an autosomal recessive disorder caused by deficiency of galactocerebrosidase (GALC). The infantile form, which accounts for 90% of cases, presents at 3-6 months with irritability, feeding difficulties, spasticity, peripheral neuropathy, and optic atrophy, progressing rapidly to death by age 2. Later-onset forms show slower progression with spastic paraparesis and neuropathy. Diagnosis is based on deficient GALC activity, psychosine elevation, and genetic testing. HSCT in presymptomatic infants, enabled by newborn screening, is the only treatment with meaningful benefit; once symptoms are established, the response is limited.

### Alexander Disease

Alexander disease is unique among leukodystrophies in that it is caused by de novo dominant mutations in GFAP (glial fibrillary acidic protein) and primarily affects astrocytes rather than oligodendrocytes. The pathological hallmark is Rosenfeld fibers, which are eosinophilic inclusions in astrocytes. Type I (infantile) presents with macrocephaly, seizures, spasticity, and cognitive decline, with frontal-predominant white matter disease on MRI. Type II (juvenile/adult) features bulbar dysfunction, palatal myoclonus, ataxia, and spasticity, with brainstem and cerebellar predominance and cervical cord atrophy. No specific treatment exists; care is supportive.

### Canavan Disease

Canavan disease is an autosomal recessive disorder caused by deficiency of aspartoacylase (ASPA), leading to accumulation of N-acetylaspartic acid (NAA) in the brain. It presents in infancy with macrocephaly, hypotonia evolving to spasticity, visual impairment, and intellectual disability. MRI shows diffuse white matter involvement with characteristic subcortical U-fiber involvement. MR spectroscopy reveals a markedly elevated NAA peak, which is diagnostic. Diagnosis is confirmed by elevated urine NAA, deficient ASPA activity, and genetic testing.

![Table comparing key features of major leukodystrophies including enzyme deficiency, genetics, and treatment options](images/leukodystrophy-comparison.jpg)

## Other Important Neurometabolic Diseases

### Cerebrotendinous Xanthomatosis (CTX)

CTX is an autosomal recessive disorder caused by deficiency of sterol 27-hydroxylase (CYP27A1), leading to accumulation of cholestanol in the brain, tendons, and other tissues. The clinical presentation typically evolves from childhood diarrhea to juvenile cataracts, tendon xanthomas, and progressive cerebellar ataxia, spasticity, and cognitive decline. Critically, CTX is treatable: chenodeoxycholic acid supplementation prevents disease progression if started early. Diagnosis rests on elevated serum cholestanol, elevated urine bile alcohols, and CYP27A1 mutation analysis.

### Niemann-Pick Type C

Niemann-Pick type C is an autosomal recessive disorder caused by mutations in NPC1 (95%) or NPC2, resulting in impaired intracellular cholesterol trafficking. Age of onset is variable, spanning infantile, juvenile, and adult forms. Neurological features include vertical supranuclear gaze palsy (especially downward gaze), cerebellar ataxia, dystonia, dementia, gelastic cataplexy, and psychiatric symptoms. Diagnosis involves filipin staining of skin fibroblasts, plasma oxysterols as a biomarker, and genetic testing. Miglustat, a substrate reduction therapy, may slow neurological progression.

### Phenylketonuria (PKU)

PKU is an autosomal recessive disorder caused by deficiency of phenylalanine hydroxylase (PAH). Untreated, it leads to severe intellectual disability, seizures, behavioral disturbances, eczema, and a musty odor. Detection on newborn screening and dietary phenylalanine restriction prevents neurological damage. MRI in untreated or poorly treated patients shows periventricular white matter T2 hyperintensities. Sapropterin (BH4) is available for responsive patients, and pegvaliase (enzyme substitution) is an option for adults.

![Diagnostic flowchart for neurometabolic diseases presenting with progressive neurological decline and white matter abnormalities](images/neurometabolic-workup.jpg)

## Clinical Pearls

MRI pattern recognition is the single most valuable tool in narrowing the differential diagnosis of leukodystrophies, with anterior versus posterior predominance and presence or absence of contrast enhancement being the key distinguishing features. X-linked adrenoleukodystrophy should be excluded in any male with adrenal insufficiency, as neurological symptoms may develop years later, and newborn screening is transforming early detection. Cerebrotendinous xanthomatosis is one of the most treatable leukodystrophies; the combination of cataracts, tendon xanthomas, and cerebellar ataxia should prompt cholestanol measurement. Gene therapy is now approved or in advanced trials for several leukodystrophies (MLD, X-ALD), making early and presymptomatic diagnosis through newborn screening critically important. Vertical supranuclear gaze palsy in a child or young adult with cognitive decline or psychiatric symptoms should prompt evaluation for Niemann-Pick type C.

## References

1. van der Knaap MS, Bugiani M. Leukodystrophies: a proposed classification system based on pathological changes and pathogenetic mechanisms. *Acta Neuropathol*. 2017;134(3):351-382.
2. Engelen M, Kemp S, de Visser M, et al. X-linked adrenoleukodystrophy (X-ALD): clinical presentation and guidelines for diagnosis, follow-up, and management. *Orphanet J Rare Dis*. 2012;7:51.
3. Fumagalli F, Calbi V, Natali Sora MG, et al. Lentiviral haematopoietic stem-cell gene therapy for early-onset metachromatic leukodystrophy: long-term results. *Lancet*. 2022;399(10322):372-383.
4. Patterson MC, Mengel E, Vanier MT, et al. Treatment of neurological manifestations of Niemann-Pick disease type C. *Expert Rev Neurother*. 2020;20(7):735-747.